Recommended Topic Related To:

Flucelvax

"Feb. 21, 2013 -- With flu season dragging on, supplies of the children's version of the flu drug Tamiflu continue to dwindle nationwide, according to the drug's maker.

The liquid medicine, called Tamiflu OS (for oral suspension), is a"...

Flucelvax

Flucelvax Side Effects Center

Reviewed by Melissa Conrad Stöppler, MD

Flucelvax is an influenza virus vaccine that is used to help immunize against influenza or "the flu" in people ages 18 and older. Flucelvax belongs to a class of drugs called inactivated influenza virus vaccines. Side effects of Flucelvax may include, but are not limited to, pain or redness at the injection site, headache, fatigue, muscle aches, and generally feeling unwell (malaise).

Flucelvax is given as a single 0.5 mL dose for intramuscular injection. There is no available data to assess drug interactions between Flucelvax and other vaccines. The safety and effectiveness of Flucelvax in pregnant women and nursing mothers has not been established. Therefore, this vaccine should only be used during pregnancy if clearly needed.

Our Flucelvax Influenza Virus Vaccine Suspension for Intramuscular Injection Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

What is Prescribing information?

The FDA package insert formatted in easy-to-find categories for health professionals and clinicians.

Flucelvax FDA Prescribing Information: Side Effects
(Adverse Reactions)

SIDE EFFECTS

Overall, the most common ( ≥ 10 %) solicited adverse reactions occurring in adults 18 to 64 years of age within 7 days of vaccination with FLUCELVAX were pain at the injection site (28%), erythema at the injection site (13%), headache (16%), fatigue (12%), myalgia (11%) and malaise (10%). The most common ( ≥ 10%) solicited adverse reactions occurring in adults 65 years of age and older within 7 days of vaccination were erythema at the injection site (10%), fatigue (11%), headache (10%) and malaise (10%).

Clinical Trials Experience

Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a vaccine cannot be directly compared to rates in clinical studies of another vaccine, and may not reflect rates observed in clinical practice.

The safety of FLUCELVAX was evaluated in seven randomized, controlled studies conducted in the US, Europe and New Zealand. The safety population includes 5709 adults 18 through 64 years of age and 572 adults 65 years of age and older administered Flucelvax.

In all studies, solicited local injection site and systemic adverse reactions were collected from subjects who completed a symptom diary card for 7 days following vaccination.

One of the 7 clinical trials (Study 1) was a randomized, double-blind, placebo-controlled study that evaluated three vaccines including: FLUCELVAX (N=3813), placebo (N=3894) and another influenza vaccine. The population was 18 through 49 years of age (mean 32.8 years), 55% were female and 84% were Caucasian. Solicited adverse reactions for FLUCELVAX and placebo are summarized in Table 1.

Table 1: Solicited Adverse Reactions in the Safety Population1 Reported Within 7 Days of Vaccination in Study 1

  Adults 18 through 49 Years
Percentages (%)
FLUCELVAX
N=3813
Placebo2
N=3894
Local adverse reactions
  Injection site pain 30 10
  Erythema 13 10
  Induration 6 3
  Swelling 6 3
  Ecchymosis 4 4
Systemic adverse reactions
  Headache 15 15
  Fatigue 10 10
  Myalgia 12 7
  Malaise 8 6
  Chills 6 6
  Arthralgia 3 3
  Sweating 3 3
  Fever ( ≥ 38° C) 1 < 1
1Safety population: all subjects in the exposed population who provided post vaccination safety data
2Placebo: 0.5 mL Phosphate Buffered Saline

Study 2 was a randomized, double-blind study comparing FLUCELVAX (N=1330) to a U.S. licensed inactivated influenza vaccine (N=1324) in adults 18 years of age or older. The mean age was 43.7 years of age for adults 18 through 64 years of age and 71.3 years of age for adults 65 years of age and older; 57% of subjects were female and 100% were Caucasian. The safety data observed are summarized in Table 2.

Table 2: Solicited Adverse Reactions in the Safety Population1 Reported Within 7 Days of Vaccination in Study 2

  Adults 18 through 64 Years Adults 65 Years of Age and Older
Percentages (%)
FLUCELVAX
N=821
Comparator2
N=841
FLUCELVAX
N=509
Comparator2
N=483
Local adverse reactions
Injection site pain 20 15 8 4
Erythema 14 15 10 11
Induration 6 6 5 4
Swelling 4 4 4 2
Ecchymosis 3 3 4 4
Systemic adverse reactions
Headache 12 11 10 11
Fatigue 11 11 11 13
Myalgia 7 8 6 8
Malaise 11 11 10 11
Chills 4 4 3 4
Arthralgia 5 5 6 7
Sweating 5 4 7 8
Fever ( ≥ 38°C) 1 1 < 1 1
1Safety population: all subjects in the exposed population who provided post vaccination safety data
2AGRIFLU

Unsolicited adverse events, including serious adverse events (SAEs), were collected for 21 days after vaccination in five studies. In adults 18 through 64 years of age (N=4038), 13% (284 out of 2266) of subjects who received FLUCELVAX and 13% (224 out of 1772) of subjects who received a U.S. licensed inactivated influenza vaccine reported at least one unsolicited adverse event within 21 days after vaccination. The most commonly reported unsolicited adverse events after FLUCELVAX vaccination were rhinitis (3%), headache (2%) and oropharyngeal pain (2%). In adults 65 years of age and older (N=2013), 11% (110 out of 997) of subjects who received FLUCELVAX and 9% (95 out of 1016) of subjects who received a U.S. licensed comparator vaccine reported at least one unsolicited adverse event within 21 days after vaccination. Within this age group, the most commonly reported unsolicited adverse events after FLUCELVAX vaccination were rhinitis (3%) and cough (2%). In both age groups, all other unsolicited adverse events were reported in 1% or fewer subjects.

In the seven controlled studies of FLUCELVAX, serious adverse events were collected for a duration of 21 days in two studies and for a duration of 6 to 9 months in five studies. The rates (in all seven controlled studies) of serious adverse events among adults 18 through 64 years of age were 1% (84 out of 6388) in groups that received FLUCELVAX, 1% (55 out of 5745) in groups that received US licensed influenza vaccines and 1% (37 out of 3894) in groups that received placebo. The rates of serious adverse events among adults 65 years of age and older were 4% (36 out of 997) in groups that received FLUCELVAX and 4% (44 out of 1016) in groups that received a US licensed comparator vaccine.

Postmarketing Experience

The following additional adverse events have been identified during post-approval use of FLUCELVAX. Because these events are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to the vaccine.

Immune System Disorders

Anaphylactic reaction, angioedema

Skin and Subcutaneous Tissue Disorders

Generalized skin reactions including pruritus, urticaria or non-specific rash.

Read the entire FDA prescribing information for Flucelvax (Influenza Virus Vaccine for Injection) »

A A A

Report Problems to the Food and Drug Administration

 

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.


Women's Health

Find out what women really need.


NIH talks about Ebola on WebMD